Two Sigma Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Two Sigma Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+6,797	New	+$226K	0.02%	1073
2024 Q3	–	Sell	-16,253	Closed	-$284K	–	3618
2024 Q2	$264K	Buy	+16,253	New	+$250K	﹤0.01%	2110
2023 Q3	–	Sell	-15,494	Closed	-$117K	–	3468
2023 Q2	$117K	Sell	15,494 -77,963	-83%	-$632K	﹤0.01%	2306
2023 Q1	$827K	Sell	93,457 -14,005	-13%	-$138K	0.02%	940
2022 Q4	$980K	Buy	+107,462	New	+$938K	0.03%	698
2022 Q3	–	Sell	-127,020	Closed	-$1.12M	–	3085
2022 Q2	$955K	Buy	127,020 +94,471	+290%	+$823K	0.03%	553
2022 Q1	$306K	Buy	32,549 +19,978	+159%	+$167K	0.01%	1389
2021 Q4	$101K	Sell	12,571 -41,574	-77%	-$375K	﹤0.01%	1181
2021 Q3	$527K	Sell	54,145 -9,095	-14%	-$85.2K	0.02%	747
2021 Q2	$626K	Buy	+63,240	New	+$669K	0.02%	561
2020 Q4	–	Sell	-12,972	Closed	-$124K	–	1942
2020 Q3	$117K	Buy	12,972 +800	+7%	+$8.46K	﹤0.01%	1168
2020 Q2	$150K	Sell	12,172 -3,837	-24%	-$43.4K	﹤0.01%	1182
2020 Q1	$144K	Buy	16,009 +2,712	+20%	+$27.8K	﹤0.01%	1103
2019 Q4	$130K	Buy	+13,297	New	+$119K	﹤0.01%	2177
2019 Q3	–	Sell	-15,274	Closed	-$141K	–	2451
2019 Q2	$141K	Sell	15,274 -73,480	-83%	-$886K	﹤0.01%	1802
2019 Q1	$1.39M	Buy	88,754 +72,071	+432%	+$1.27M	0.01%	442
2018 Q4	$257K	Sell	16,683 -31,338	-65%	-$642K	﹤0.01%	1512
2018 Q3	$1.03M	Buy	48,021 +37,062	+338%	+$860K	0.01%	1014
2018 Q2	$267K	Sell	10,959 -53,590	-83%	-$1.09M	﹤0.01%	2145
2018 Q1	$1.1M	Buy	64,549 +6,565	+11%	+$128K	0.01%	1199
2017 Q4	$1.1M	Buy	+57,984	New	+$872K	0.03%	399
2017 Q2	–	Sell	-16,595	Closed	-$533K	–	1173
2017 Q1	$533K	Sell	16,595 -10,388	-38%	-$355K	0.1%	182
2016 Q4	$978K	Sell	26,983 -28,113	-51%	-$1.12M	0.33%	57
2016 Q3	$2.54M	Buy	55,096 +48,111	+689%	+$2.51M	0.86%	12
2016 Q2	$351K	Buy	6,985 +3,163	+83%	+$168K	0.19%	153
2016 Q1	$205K	Buy	+3,822	New	+$224K	0.26%	134

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Two Sigma Securities's TEVA Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 6,797 shares worth $230K. The stake represents 0.02% of the portfolio and ranks #1073 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in TEVA as recently as Q2 2024.

Two Sigma Securities first reported a position in TEVA in Q1 2016 and has held it in 26 quarters since. The position peaked at $2.54M in Q3 2016. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Two Sigma Securities held 6,797 shares of Teva Pharmaceuticals worth $230K as of Q2 2026.
Teva Pharmaceuticals was a new Two Sigma Securities position in Q2 2026.
Teva Pharmaceuticals made up 0.02% of Two Sigma Securities's portfolio in Q2 2026, its #1073 holding.
Two Sigma Securities first reported a position in Teva Pharmaceuticals in Q1 2016 and has held it in 26 quarters since.
Two Sigma Securities's Teva Pharmaceuticals position peaked at $2.54M in Q3 2016.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.